Loading
A phase 1/2 trial of SHR-8068, Bevacizumab, Leucovorin (folinic acid), Adebrelimab and Capecitabine in advanced solid tumours, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors is a phase 1/2 interventional study registered as NCT06703177 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 876 participants planned, started 2025-02-18 and due to reach its primary completion in 2026-01-01. Interventions recorded: SHR-1826, SHR-4642, SHR-9839, SHR-8068, Bevacizumab Injection and Fluorouracil Injection.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Capecitabine and the tag pipeline.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Bevacizumab and the tag pipeline.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Shares Leucovorin (folinic acid), Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/